Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A.
2015.
Clinical characteristics of patients with relapsed multiple myeloma.. Cancer Treat Rev. 41(10):827-35.
Siegel D, Martin T, Nooka A, R Harvey D, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K et al..
2013.
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.. Haematologica. 98(11):1753-61.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..
2014.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.